$55.7 Million is the total value of Healthcare Value Capital, LLC's 17 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 52.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | PFIZER INC | $8,398,000 | -1.8% | 250,000 | 0.0% | 15.09% | +3.2% | |
| NVLNF | NOVELION THERAPEUTICS INC | $7,674,000 | -14.1% | 831,440 | 0.0% | 13.79% | -9.7% | |
| DEPO | Buy | DEPOMED INC | $5,907,000 | +34.5% | 550,000 | +57.1% | 10.61% | +41.3% |
| GILD | GILEAD SCIENCES INC | $5,309,000 | +4.2% | 75,000 | 0.0% | 9.54% | +9.5% | |
| BIS | Buy | PROSHARES TRcall | $4,852,000 | +598.1% | 200,000 | +700.0% | 8.72% | +633.2% |
| GILD | GILEAD SCIENCES INCcall | $4,247,000 | +4.2% | 60,000 | 0.0% | 7.63% | +9.5% | |
| CRY | New | CRYOLIFE INCput | $3,990,000 | – | 200,000 | +100.0% | 7.17% | – |
| AGN | ALLERGAN PLC | $3,646,000 | +1.7% | 15,000 | 0.0% | 6.55% | +6.9% | |
| VIXY | New | PROSHARES TR IIcall | $2,658,000 | – | 250,000 | +100.0% | 4.78% | – |
| TEVA | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $2,492,000 | +3.5% | 75,000 | 0.0% | 4.48% | +8.8% | |
| AMRN | AMARIN CORP PLCspons adr new | $1,814,000 | +26.0% | 450,000 | 0.0% | 3.26% | +32.4% | |
| FLDM | Buy | FLUIDIGM CORP DEL | $1,456,000 | -7.0% | 360,500 | +31.1% | 2.62% | -2.3% |
| DEPO | DEPOMED INCcall | $1,074,000 | -14.4% | 100,000 | 0.0% | 1.93% | -10.1% | |
| IMMU | IMMUNOMEDICS INCcall | $883,000 | +36.5% | 100,000 | 0.0% | 1.59% | +43.4% | |
| BIS | New | PROSHARES TRultsh nasd biot | $606,000 | – | 25,000 | +100.0% | 1.09% | – |
| FLDM | Buy | FLUIDIGM CORP DELcall | $606,000 | +112.6% | 150,000 | +200.0% | 1.09% | +123.6% |
| FCSC | New | FIBROCELL SCIENCE INCcall | $40,000 | – | 10,000 | +100.0% | 0.07% | – |
| FCSC | Exit | FIBROCELL SCIENCE INC | $0 | – | -15,923 | -100.0% | -0.06% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -31,850 | -100.0% | -0.59% | – |
| CRY | Exit | CRYOLIFE INC | $0 | – | -150,000 | -100.0% | -4.27% | – |
| IPXL | Exit | IMPAX LABORATORIES INCcall | $0 | – | -200,000 | -100.0% | -4.33% | – |
| AMRI | Exit | ALBANY MOLECULAR RESH INC | $0 | – | -302,400 | -100.0% | -7.26% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -25,000 | -100.0% | -10.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-10
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC | 20 | Q3 2021 | 31.3% |
| GLAXOSMITHKLINE PLC | 20 | Q3 2021 | 16.1% |
| PFIZER INC | 19 | Q3 2021 | 17.9% |
| TYME TECHNOLOGIES INC | 17 | Q3 2021 | 40.3% |
| ASTRAZENECA PLC | 14 | Q3 2021 | 12.9% |
| QUEST DIAGNOSTICS INC | 14 | Q3 2016 | 9.5% |
| CRYOLIFE INC | 13 | Q1 2017 | 6.6% |
| ANTARES PHARMA INC | 13 | Q3 2021 | 6.7% |
| AMARIN CORP PLC | 13 | Q3 2021 | 4.9% |
| CYTOKINETICS INC | 13 | Q3 2016 | 1.7% |
View Healthcare Value Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NOVELION THERAPEUTICS INC. | September 20, 2019 | 1,400,000 | 7.4% |
View Healthcare Value Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| SC 13D/A | 2019-09-20 |
View Healthcare Value Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.